zaleplon

Trade name: sonata

Small moleculeapproved

Approved

Aug 13, 1999

Zaleplon is a nonbenzodiazepine hypnotic from the pyrazolopyrimidine class and is indicated for the short-term treatment of insomnia. While Zaleplon is a hypnotic agent with a chemical structure unrelated to benzodiazepines, barbiturates, or other drugs with known hypnotic properties, it interacts with the gamma-aminobutyric acid-benzodiazepine (GABABZ) receptor complex. Subunit modulation of the GABABZ receptor chloride channel macromolecular complex is hypothesized to be responsible for some of the pharmacological properties of benzodiazepines, which include sedative, anxiolytic, muscle relaxant, and anticonvulsive effects in animal models. Zaleplon also binds selectively to the CNS GABAA-receptor chloride ionophore complex at benzodiazepine(BZ) omega-1 (BZ1, ο1) receptors. Zaleplon exerts its action through subunit modulation of the GABABZ receptor chloride channel macromolecular complex. Zaleplon also binds selectively to the brain omega-1 receptor located on the alpha subunit of the GABA-A/chloride ion channel receptor complex and potentiates t-butyl-bicyclophosphorothionate (TBPS) binding. Zaleplon is marketed under the brand names Sonata, Starnoc, and Andante. — NCATS

Clinical trial activity

10 trials · 17 clinical orgs · 14 marketing orgs

Phase 1
3
Phase 2
4
Phase 3
1
Phase 4
1

Earliest trial started Jan 1, 2004 (NCT00694187)

Timeline

1990s

  1. Aug 13, 1999

    American Home Products — Earliest FDA Approval

  2. Aug 13, 1999

    Pfizer — NDA Secondary Org

  3. Aug 13, 1999

    American Home Products — NDA Organization

2000s

  1. Jan 1, 2004

    Teva — Earliest Phase 1 Sponsor(trial)

  2. Jun 6, 2008

    Aurobindo Pharma — Marketing Organization

  3. Jun 6, 2008

    Mylan — Marketing Organization

  4. Jun 6, 2008

    Teva — Marketing Organization

  5. Jun 6, 2008

    Unichem — Marketing Organization

  6. Jun 6, 2008

    Upsher-Smith Laboratories — Marketing Organization

  7. Jun 6, 2008

    West-Ward Pharmaceutical — Marketing Organization

  8. Jun 6, 2008

    Natco Pharma — Marketing Organization

  9. Jun 20, 2008

    Chartwell Pharmaceuticals — Marketing Organization

  10. Jun 20, 2008

    Cipla — Marketing Organization

  11. Nov 25, 2008

    Hikma — Marketing Organization

  12. Sep 17, 2009

    Orbion Pharms — Marketing Organization

  13. Sep 17, 2009

    Orchid Pharma — Marketing Organization

2010s

  1. Jan 1, 2010

    Earliest Phase 2 Sponsor(trial)

  2. Jan 1, 2015

    Earliest Phase 3 Sponsor(trial)

Indications

Mechanism of action

Approval history

  • approvedAug 13, 1999

Chemistry & pharmacology

Loading structure…

SMILES

CCN(C(C)=O)C1=CC(=CC=C1)C2=CC=NC3=C(C=NN23)C#N
Mol. weight
305.3339 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Achiral Molecule
Inorganic
No
Polymer
No
Delivery
Oral
Availability
Prescription Only

Oral

Yes

Parenteral

No

Topical

No

Black box warning

Sources

Also known as

  • 3'-(3-cyanopyrazolo(1,5-alpha)pyrimidin-7-yl)-n-ethylacetanilide
  • 3'-(3-cyanopyrazolo(1,5-a)pyrimidin-7-yl)-n-ethylacetanilide
  • 3'-(3-cyanopyrazolo(1,5-a)pyrimidin-7-yl)-n-ethylacetanilide
  • acetamide, n-(3-(3-cyanopyrazolo(1,5-a)pyrimidin-7-yl)phenyl)-n-ethyl-
  • cl 284846
  • cl 284,846
  • cl 284,846
  • cl-284846
  • cl-284846
  • cl-284846
  • cl-284846
  • cl284,846
  • l846
  • l846
  • l 846
  • l-846
  • l-846
  • l-846
  • ljc 10846
  • ljc 10846
  • ljc-10846
  • ljc-10846
  • n-(3-(3-cyanopyrazolo(1,5-a)pyrimidin-7-yl)phenyl)-n-ethylacetamide
  • skp-1041
  • sonata
  • sonata
  • sonata
  • sonata
  • sonata
  • sonata
  • starnoc
  • zal-846
  • zal-846
  • zal-846
  • zaleplon
  • zaleplon
  • zaleplon
  • zaleplon
  • zaleplon
  • zaleplon
  • zaleplon
  • zaleplon
  • zaleplon
  • zaleplon
  • zaleplon
  • zaleplon
  • zaleplon
  • zelepion

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT02374567Phase 3Jan 1, 2015Gottfried Wilhelm Leibniz Universität Hannover
NCT03489304Phase 2Apr 3, 2014University of Pennsylvania
NCT01277107Phase 2Jan 1, 2011Intec Pharma Ltd.
NCT01159652Phase 4Oct 1, 2010American Academy of Sleep Medicine, St. Luke's Hospital, Chesterfield, Missouri
NCT00878553Phase 2May 1, 2010Broward Research Group, Clinilabs, Emsellem MD PC, INC Research, Neurotrials Inc., Sleep Disorders Center of Georgia, Somnus Therapeutics, Inc., Vince & Associates
NCT00620620Phase 1Feb 1, 2008Alexza Pharmaceuticals, Inc.
NCT00829998Phase 1Feb 1, 2004Novum Pharmaceutical Research Services, Teva
NCT00829868Phase 1Feb 1, 2004Novum Pharmaceutical Research Services, Teva
NCT00694317N/AFeb 1, 2004Novum Pharmaceutical Research Services, Roxane Laboratories
NCT00694187N/AJan 1, 2004Novum Pharmaceutical Research Services, Roxane Laboratories
Showing 10 of 10 trials
Page 1 / 1

Organizations

Research & Development (17)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Novum Pharmaceutical Research ServicesFor profit4022004
Roxane LaboratoriesFor profit2212004
TevaFor profit2212004
Alexza Pharmaceuticals, Inc.For profit1112008
American Academy of Sleep MedicineAcademic/Hospital1012010
Broward Research GroupAcademic/Hospital1012010
ClinilabsFor profit1012010
Emsellem MD PCAcademic/Hospital1012010
Gottfried Wilhelm Leibniz Universität HannoverAcademic/Hospital1112015
INC ResearchFor profit1012010
Intec Pharma Ltd.For profit1112011
Neurotrials Inc.For profit1012010
Sleep Disorders Center of GeorgiaAcademic/Hospital1012010
Somnus Therapeutics, Inc.For profit1112010
St. Luke's Hospital, Chesterfield, MissouriAcademic/Hospital1112010
University of PennsylvaniaAcademic/Hospital1112014
Vince & AssociatesFor profit1012010
17 organizations
Page 1 / 1

Marketing (15)

OrganizationOrg typeRelationshipDate
American Home ProductsFor profitNDAAug 13, 1999
Aurobindo PharmaFor profitMKTGJun 6, 2008
Chartwell PharmaceuticalsFor profitMKTGJun 20, 2008
CiplaFor profitMKTGJun 20, 2008
HikmaFor profitMKTGNov 25, 2008
HikmaFor profitSYNJun 6, 2008
MylanFor profitMKTGJun 6, 2008
Natco PharmaFor profitMKTGJun 6, 2008
Orbion PharmsFor profitMKTGSep 17, 2009
Orchid PharmaFor profitMKTGSep 17, 2009
PfizerFor profitNDA2Aug 13, 1999
TevaFor profitMKTGJun 6, 2008
UnichemFor profitMKTGJun 6, 2008
Upsher-Smith LaboratoriesFor profitMKTGJun 6, 2008
West-Ward PharmaceuticalFor profitMKTGJun 6, 2008